Form 4: Elevance Health EVP & CFO Mark Kaye Reports Stock Transactions

Elevance Health's EVP & CFO, Mark Kaye, reports the acquisition and disposal of company stock and stock options.

Summary

• Mark Kaye, EVP & CFO of Elevance Health, reported transactions involving the company's stock on March 3, 2025.
• These transactions included the disposal of 270 shares to cover tax liabilities related to vesting restricted stock at a price of $395.5 per share.
• Kaye also acquired 3,604 restricted share units, which vest in three annual installments starting March 3, 2026.
• Additionally, Kaye was granted an employee stock option to purchase 13,713 shares of common stock at an exercise price of $395.5, exercisable in three annual installments beginning March 3, 2026.
• Following these transactions, Kaye directly owns 19,961 shares of common stock and 13,713 shares via employee stock options, and 23,565 shares including restricted share units.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the filing represents routine transactions related to executive compensation. There are no indications of unusual or concerning activity.

Positives

• The granting of stock options and restricted share units to the CFO aligns his interests with those of the shareholders.
• The vesting schedule of the restricted share units (2026-2028) encourages long-term commitment from the CFO.

Future Outlook

The reported transactions reflect ongoing compensation and equity ownership adjustments for a key executive, suggesting continued alignment with company performance.

Industry Context

Form 4 filings are routine disclosures for corporate insiders and are closely watched by investors for insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Stock option grants and restricted stock units are standard components of executive compensation packages in publicly traded companies, including Elevance Health's peers like UnitedHealth Group (UNH) and CVS Health (CVS).
• The vesting schedules and exercise prices are generally structured to incentivize long-term value creation and retention, aligning with industry norms.
• The size of the grants and the executive's existing holdings are typical for a CFO role in a company of Elevance Health's size and market capitalization.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders.
• They provide transparency into executive compensation and ownership, which can influence investor confidence.

Key Dates